NO339056B1 - Fremgangsmåte til å amplifisere et Chordopoxvirus. - Google Patents
Fremgangsmåte til å amplifisere et Chordopoxvirus. Download PDFInfo
- Publication number
- NO339056B1 NO339056B1 NO20040158A NO20040158A NO339056B1 NO 339056 B1 NO339056 B1 NO 339056B1 NO 20040158 A NO20040158 A NO 20040158A NO 20040158 A NO20040158 A NO 20040158A NO 339056 B1 NO339056 B1 NO 339056B1
- Authority
- NO
- Norway
- Prior art keywords
- virus
- temperature
- cells
- mva
- procedure
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 61
- 238000000034 method Methods 0.000 title claims description 32
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 31
- 241000700618 Vaccinia virus Species 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 230000000644 propagated effect Effects 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 64
- 238000002474 experimental method Methods 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000002238 attenuated effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000700647 Variola virus Species 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920001993 poloxamer 188 Polymers 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 241000700570 unidentified entomopoxvirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000587120 Vaccinia virus Ankara Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 241001135961 Amsacta moorei entomopoxvirus Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001137864 Camelpox virus Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 206010069540 Generalised vaccinia Diseases 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101122 | 2001-07-18 | ||
| PCT/EP2002/007280 WO2003008533A2 (en) | 2001-07-18 | 2002-07-02 | Method for virus propagation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20040158L NO20040158L (no) | 2004-01-13 |
| NO339056B1 true NO339056B1 (no) | 2016-11-07 |
Family
ID=8160630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040158A NO339056B1 (no) | 2001-07-18 | 2004-01-13 | Fremgangsmåte til å amplifisere et Chordopoxvirus. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6924137B2 (enExample) |
| EP (1) | EP1412486B1 (enExample) |
| JP (2) | JP4700907B2 (enExample) |
| KR (1) | KR100908377B1 (enExample) |
| CN (1) | CN100513560C (enExample) |
| AU (1) | AU2002314201B2 (enExample) |
| BR (2) | BRPI0211276B1 (enExample) |
| CA (1) | CA2450206C (enExample) |
| DE (1) | DE60223812T2 (enExample) |
| DK (1) | DK1412486T3 (enExample) |
| EA (1) | EA006628B1 (enExample) |
| HU (1) | HUP0400393A3 (enExample) |
| IL (2) | IL158927A0 (enExample) |
| MX (1) | MXPA04000326A (enExample) |
| NO (1) | NO339056B1 (enExample) |
| NZ (1) | NZ529914A (enExample) |
| PL (1) | PL205926B1 (enExample) |
| UA (1) | UA82466C2 (enExample) |
| WO (1) | WO2003008533A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1335987T4 (en) * | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
| WO2004022729A1 (en) * | 2002-09-05 | 2004-03-18 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| TWI638829B (zh) | 2012-07-10 | 2018-10-21 | 法商傳斯堅公司 | 分枝桿菌抗原疫苗 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| US10765731B2 (en) | 2014-01-09 | 2020-09-08 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| ES3011733T3 (en) | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| US10913063B2 (en) * | 2016-07-12 | 2021-02-09 | EMULATE, Inc. | Removing bubbles in a microfluidic device |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| SG11201912429RA (en) | 2017-06-21 | 2020-01-30 | Transgene Sa | Personalized vaccine |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| AU2024241503A1 (en) | 2023-03-17 | 2025-08-14 | Albert-Ludwigs-Universität Freiburg | Hbv antigen formulation for treating hepatitis b |
| WO2025172435A1 (en) | 2024-02-13 | 2025-08-21 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Hbv antigen formulation for treating hepatitis b |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2734660A1 (de) * | 1976-08-05 | 1978-02-09 | Anvar | Verfahren zur herstellung eines myxomatose-impfstoffs |
| WO1995022978A1 (en) * | 1994-02-23 | 1995-08-31 | Anton Mayr | Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60202827A (ja) * | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| WO1997012032A1 (en) * | 1995-09-27 | 1997-04-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| EP0912724B1 (en) * | 1996-07-15 | 2009-12-09 | The Government of The United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| DK1335987T4 (en) * | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
-
2002
- 2002-02-07 UA UA2004010355A patent/UA82466C2/uk unknown
- 2002-07-02 HU HU0400393A patent/HUP0400393A3/hu unknown
- 2002-07-02 JP JP2003514077A patent/JP4700907B2/ja not_active Expired - Fee Related
- 2002-07-02 WO PCT/EP2002/007280 patent/WO2003008533A2/en not_active Ceased
- 2002-07-02 CA CA2450206A patent/CA2450206C/en not_active Expired - Fee Related
- 2002-07-02 AU AU2002314201A patent/AU2002314201B2/en not_active Ceased
- 2002-07-02 EA EA200400195A patent/EA006628B1/ru not_active IP Right Cessation
- 2002-07-02 US US10/483,707 patent/US6924137B2/en not_active Expired - Lifetime
- 2002-07-02 NZ NZ529914A patent/NZ529914A/en not_active IP Right Cessation
- 2002-07-02 CN CNB02814421XA patent/CN100513560C/zh not_active Expired - Fee Related
- 2002-07-02 DE DE60223812T patent/DE60223812T2/de not_active Expired - Lifetime
- 2002-07-02 MX MXPA04000326A patent/MXPA04000326A/es active IP Right Grant
- 2002-07-02 DK DK02740758T patent/DK1412486T3/da active
- 2002-07-02 BR BRPI0211276A patent/BRPI0211276B1/pt unknown
- 2002-07-02 KR KR1020047000786A patent/KR100908377B1/ko not_active Expired - Fee Related
- 2002-07-02 EP EP02740758A patent/EP1412486B1/en not_active Revoked
- 2002-07-02 IL IL15892702A patent/IL158927A0/xx unknown
- 2002-07-02 BR BR0211276-0A patent/BR0211276A/pt not_active IP Right Cessation
- 2002-07-02 PL PL366897A patent/PL205926B1/pl unknown
-
2003
- 2003-11-18 IL IL158927A patent/IL158927A/en not_active IP Right Cessation
-
2004
- 2004-01-13 NO NO20040158A patent/NO339056B1/no not_active IP Right Cessation
-
2010
- 2010-11-22 JP JP2010259770A patent/JP5154632B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2734660A1 (de) * | 1976-08-05 | 1978-02-09 | Anvar | Verfahren zur herstellung eines myxomatose-impfstoffs |
| WO1995022978A1 (en) * | 1994-02-23 | 1995-08-31 | Anton Mayr | Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament |
Non-Patent Citations (3)
| Title |
|---|
| Drexler et al. "Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells". Journal of General Virology (1998), 79, 347-352., Dated: 01.01.0001 * |
| SLONIM D et al. "Influence of the incubation temperature on the dynamics of reproduction and plaque formation of three strains of Vaccinia virus in cell cultures." JOURNAL OF HYGIENE, EPIDEMIOLOGY, MICROBIOLOGY AND IMMUNOLOGY. CZECHOSLOVAKIA 1972, vol. 16, no. 4,1972, pages 473-479 , Dated: 01.01.0001 * |
| TAN W et al. "Study of the Properties of Plaques of Recombinant Vaccinia Virus with Hepatitis B Surface Antigen Gene Inserted at TK Site". Chinese Journal of Virology, March 1990, side 12-18., Dated: 01.01.0001 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5154632B2 (ja) | ウイルス増殖法 | |
| CN1934243B (zh) | 用于病毒生产的永生化的禽类细胞系 | |
| Sutter et al. | A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus | |
| ES2345820T3 (es) | Produccion de poxvirus con estirpes de celulas aviares adherentes o no adherentes. | |
| RU2704485C2 (ru) | Стабильные жидкие препараты вируса осповакцины | |
| US7445924B2 (en) | Modified Vaccinia Ankara virus variant and cultivation method | |
| AU2002314201A1 (en) | Method for virus propagation | |
| US8329466B2 (en) | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions | |
| JP2004535203A5 (enExample) | ||
| IL150736A (en) | Vucinic Ankara Virus Modified (MVA) | |
| CN104812894B (zh) | 新型mva病毒及其用途 | |
| HK1066245B (en) | Method for virus propagation | |
| JP2006509526A (ja) | トリ胚性幹細胞上におけるａｌｖａｃの産生 | |
| JPH05508540A (ja) | 組換え型鳩痘ウイルスワクチン | |
| Jordan et al. | An Avian Cell Line for Production of Highly Attenuated Viral Vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |